Literature DB >> 8334639

Gliosarcoma with features of chondroblastic osteosarcoma.

K Hayashi1, N Ohara, H J Jeon, S Akagi, K Takahashi, T Akagi, S Namba.   

Abstract

BACKGROUND: The occurrence of osteoid-chondral elements in gliosarcoma is extremely rare and has been reported in only two cases. A new, rare case of gliosarcoma with osteosarcomatous differentiation in a 55-year-old man and histogenesis of osteoid-chondral tissue in gliosarcoma is discussed.
METHODS: Surgically removed tumor tissues were examined immunohistochemically and electron microscopically, and a histologic examination was performed.
RESULTS: Immunohistochemical and electron microscopic studies confirmed the presence of glial, fibroblastic, and osteoid-chondral elements. A major part of the sarcomatous tissue was undifferentiated and stained only by vimentin. Some areas of osteoid-chondral tissue were positive for glial fibrillary acidic protein (GFAP).
CONCLUSIONS: These data suggest that osteoid-chondral elements came from the sarcomatous portion and GFAP positivity is not restricted to astrocytes and has been seen particularly in chondroid areas of non-glial tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8334639     DOI: 10.1002/1097-0142(19930801)72:3<850::aid-cncr2820720334>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Caterina Giannini; Sandra C Bryant; Robert B Jenkins
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

2.  Osteosarcoma cells differentiate into phenotypes from all three dermal layers.

Authors:  Scott Russinoff; Sara Miran; Ashok L Gowda; Paul A Lucas
Journal:  Clin Orthop Relat Res       Date:  2011-06-16       Impact factor: 4.176

3.  Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.

Authors:  David Cachia; Carlos Kamiya-Matsuoka; Jacob J Mandel; Adriana Olar; Matthew D Cykowski; Terri S Armstrong; Gregory N Fuller; Mark R Gilbert; John F De Groot
Journal:  J Neurooncol       Date:  2015-09-09       Impact factor: 4.130

4.  Preferential recurrence of a sarcomatous component of a gliosarcoma after boron neutron capture therapy: case report.

Authors:  Shin-Ichi Miyatake; Hiroko Kuwabara; Yoshinaga Kajimoto; Shinji Kawabata; Kunio Yokoyama; Atsushi Doi; Motomu Tsuji; Hiroshi Mori; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

5.  Childhood's gliosarcomas: pathological and therapeutical considerations on three cases and critical review of the literature.

Authors:  Maurizio Salvati; Jacopo Lenzi; Christian Brogna; Alessandro Frati; Manolo Piccirilli; Felice Giangaspero; Antonino Raco
Journal:  Childs Nerv Syst       Date:  2006-03-16       Impact factor: 1.475

6.  Primary osteosarcoma of the cerebrum with immunohistochemical and ultrastructural studies: report of a case.

Authors:  N Ohara; K Hayashi; C Shinohara; M Kamitani; T Furuta; T Yoshino; K Takahashi; K Taguchi; T Akagi
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 7.  Neoplastic cells are a rare component in human glioblastoma microvasculature.

Authors:  Fausto J Rodriguez; Brent A Orr; Keith L Ligon; Charles G Eberhart
Journal:  Oncotarget       Date:  2012-01

8.  Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma.

Authors:  Simone Frandsen; Helle Broholm; Vibeke Andrée Larsen; Kirsten Grunnet; Søren Møller; Hans Skovgaard Poulsen; Signe Regner Michaelsen
Journal:  Front Oncol       Date:  2019-12-17       Impact factor: 6.244

9.  Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature.

Authors:  Nasir Ud Din; Hira Ishtiaq; Shabina Rahim; Jamshid Abdul-Ghafar; Zubair Ahmad
Journal:  BMC Pediatr       Date:  2021-02-26       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.